Research ArticleExperimental Studies

Importance of Bevacizumab Maintenance Following Combination Chemotherapy in Human Non–small Cell Lung Cancer Xenograft Models

NOBUYUKI ISHIKURA, MIEKO YANAGISAWA, MARIKO NOGUCHI-SASAKI, TOSHIKI IWAI, KEIGO YOROZU, MITSUE KURASAWA, MASAMICHI SUGIMOTO and KANAME YAMAMOTO
Anticancer Research February 2017, 37 (2) 623-629;

Article Information

vol. 37 no. 2 623-629
PubMed 
28179309
Published By 
International Institute of Anticancer Research
Print ISSN 
0250-7005
Online ISSN 
1791-7530
History 
  • Received November 19, 2016
  • Revision received December 16, 2016
  • Accepted December 20, 2016
  • Published online February 8, 2017.
Copyright & Usage 
Copyright© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved

Author Information

  1. NOBUYUKI ISHIKURA⇑,
  2. MIEKO YANAGISAWA,
  3. MARIKO NOGUCHI-SASAKI,
  4. TOSHIKI IWAI,
  5. KEIGO YOROZU,
  6. MITSUE KURASAWA,
  7. MASAMICHI SUGIMOTO and
  8. KANAME YAMAMOTO
  1. Product Research Department, Chugai Pharmaceutical Co., Ltd., Kamakura, Japan
  1. Correspondence to: Nobuyuki Ishikura, Product Research Department, Chugai Pharmaceutical Co., Ltd. 200 Kajiwara, Kamakura, Kanagawa 247-8530, Japan. Tel: +81-467-47-6251, Fax: +81-467-45-6782, e-mail: ishikuranby{at}chugai-pharm.co.jp
View Full Text

Statistics from Altmetric.com

Cited By...

Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Reprints and Permissions
Importance of Bevacizumab Maintenance Following Combination Chemotherapy in Human Non–small Cell Lung Cancer Xenograft Models
NOBUYUKI ISHIKURA, MIEKO YANAGISAWA, MARIKO NOGUCHI-SASAKI, TOSHIKI IWAI, KEIGO YOROZU, MITSUE KURASAWA, MASAMICHI SUGIMOTO, KANAME YAMAMOTO
Anticancer Research Feb 2017, 37 (2) 623-629;
Twitter logo Facebook logo Mendeley logo

Jump to section

Keywords